There is no cure for celiac disease. The only established treatment is a strict lifelong gluten-free diet, and even that doesn’t fully heal the intestinal lining in everyone. However, several experimental therapies are in clinical trials, and some target the root immune malfunction rather than just avoiding gluten. Here’s what the current science looks like.
Why Celiac Disease Is Hard to Cure
Celiac disease is an autoimmune condition, not a food allergy or intolerance. When someone with celiac eats gluten, their immune system treats specific gluten fragments as a threat. Over 90% of people with celiac carry a genetic marker called HLA-DQ2 (the rest carry a related one called HLA-DQ8), and these markers cause immune cells to present gluten fragments to T cells in the gut lining. The T cells then launch an inflammatory attack that damages the small intestine’s finger-like projections (villi), which are responsible for absorbing nutrients.
An enzyme in the gut wall makes this worse. It chemically modifies gluten fragments so they bind even more tightly to those immune markers, amplifying the T-cell response. This means the disease involves multiple interacting systems: genetics, a specific enzyme, and a misdirected immune response. Shutting down just one part isn’t enough to eliminate the problem, which is why developing a cure has been so difficult.
How Well a Gluten-Free Diet Actually Works
A gluten-free diet is the standard treatment, and most people (about 82%) notice some improvement in symptoms after starting one. But symptom relief doesn’t necessarily mean the intestine has healed. In a study of 241 adults with celiac disease, only 34% had confirmed intestinal recovery after two years on a strict gluten-free diet. At five years, that number rose to 66%, meaning roughly one in three adults still had unhealed intestinal damage after half a decade of dietary compliance.
Part of the challenge is how little gluten it takes to cause harm. The threshold for intestinal damage is remarkably low. As little as 50 milligrams of gluten per day (roughly a small breadcrumb’s worth) consumed over three months is enough to worsen intestinal architecture. Some patients show damage at just 10 milligrams daily. A U.S. FDA assessment set the tolerable daily intake at 7 milligrams for structural damage and a strikingly low 0.015 milligrams for clinical symptoms. Completely eliminating gluten from a modern diet is extremely difficult, and hidden sources of contamination in processed foods, restaurants, and shared kitchens make truly zero-gluten living almost impossible.
Enzyme Therapies That Break Down Gluten
One approach in development tries to destroy gluten in the stomach before it reaches the small intestine. Gluten proteins are unusually resistant to normal digestive enzymes, which is why large, intact fragments survive long enough to trigger immune reactions. Latiglutenase is an enzyme supplement designed to break those fragments apart before they cause trouble.
In a Phase 2 trial, latiglutenase showed meaningful benefits for a specific subset of patients: those who still had detectable antibodies (a sign of ongoing immune activation) despite following a gluten-free diet. In this seropositive group, the highest dose reduced the severity of abdominal pain by 58%, bloating by 44%, and constipation by 104% compared to placebo over 12 weeks. It did not significantly help with nausea or diarrhea, and it showed no clear benefit for patients whose antibody levels were already under control. This therapy wouldn’t be a cure. It’s designed as a safety net alongside a gluten-free diet, protecting against accidental gluten exposure rather than allowing patients to eat gluten freely.
Tightening the Gut Barrier
Another strategy targets intestinal permeability. In celiac disease, the junctions between cells in the gut lining become looser, allowing gluten fragments to pass through and encounter immune cells more easily. Larazotide acetate is a compound designed to tighten those junctions. Early clinical trials showed it could reduce the intestinal permeability changes triggered by a gluten challenge. Like enzyme therapy, this approach is aimed at reducing damage from accidental exposure rather than eliminating the need for a gluten-free diet entirely.
Immune Tolerance: The Closest Thing to a Cure
The most ambitious therapies in development aim to retrain the immune system so it stops reacting to gluten altogether. If successful, this would address the root cause of celiac disease rather than managing its consequences.
KAN-101 is one such therapy currently in Phase 2 trials. It works by leveraging natural immune pathways in the liver to “re-educate” the T cells that drive the disease, teaching them to tolerate gluten rather than attack it. The liver already plays a role in filtering substances from digestion and suppressing unnecessary immune responses, so the idea is to harness that built-in mechanism. If this approach works, it could potentially allow people with celiac to eat gluten without triggering intestinal damage.
A different approach uses a bispecific antibody called DONQ52, also in Phase 2 trials. This therapy targets the intestinal damage directly, with its primary measure being improvement in the ratio of villous height to crypt depth, the standard indicator of how much structural damage the disease has caused. Results are not yet available.
These immune tolerance therapies are the closest thing to a potential cure on the horizon, but they remain years away from approval even if trials go well.
Hookworm Therapy: An Unusual Idea That Fell Short
One of the more unconventional approaches involved deliberately infecting celiac patients with hookworms, based on the theory that parasitic infections can calm overactive immune responses. A randomized, placebo-controlled trial of 54 people tested whether hookworm infection could restore gluten tolerance. It didn’t. Study completion rates were similar across hookworm and placebo groups, and intestinal damage worsened equally in all groups when participants ate 2 grams of gluten daily. There was one interesting finding: hookworm-treated participants reported significantly fewer gluten-related symptoms (a median of 0 to 1 adverse events per person, versus 4 for placebo) and better quality-of-life scores during periods of lower, intermittent gluten exposure. But the worms didn’t prevent the underlying intestinal damage, so this line of research has not advanced as a viable treatment.
Refractory Celiac Disease
A small percentage of celiac patients don’t improve on a gluten-free diet at all. This condition, called refractory celiac disease, comes in two forms. Type 1 involves persistent symptoms and intestinal damage but normal-looking immune cells. Type 2 is more serious, involving abnormal, clonal immune cells in the gut lining that behave almost like a pre-cancerous condition. The five-year survival rate for Type 1 is about 80%, while Type 2 drops to roughly 45%, largely because of the risk of developing a rare intestinal lymphoma. For these patients, the need for therapies beyond dietary management is especially urgent.
What This Means for People Living With Celiac
Celiac disease affects between 0.7% and 2.9% of the global population, and many cases remain undiagnosed due to the wide range of symptoms. For those who do have a diagnosis, the practical reality today is the same as it has been for decades: a strict gluten-free diet is the only proven management strategy, and it requires extraordinary vigilance given how little gluten it takes to cause harm.
The pipeline of experimental therapies is more active than it has ever been, with approaches ranging from enzyme supplements and gut barrier agents to true immune reprogramming. The enzyme and barrier therapies are closer to market but would serve as add-ons to a gluten-free diet. The immune tolerance approaches like KAN-101 represent the best hope for something resembling an actual cure, but they are still in early-stage trials. For now, a cure does not exist, but the science is closer than it has ever been to changing that.